Lemildipine NB-818; NPK-1886|cas:94739-29-4|西域试剂

Lemildipine NB-818; NPK-1886,98.06%

产品编号：Bellancom-19663| CAS NO：94739-29-4| 分子式：C₂₀H₂₂Cl₂N₂O₆| 分子量：457.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19663	￥3800.00	杭州北京（现货）
Bellancom-19663	￥6000.00	杭州北京（现货）
Bellancom-19663	￥11500.00	杭州北京（现货）
Bellancom-19663	￥18000.00	杭州北京（现货）
Bellancom-19663	￥28500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Lemildipine NB-818; NPK-1886

产品介绍

Lemildipine 是一种钙通道阻滞剂。

生物活性

Lemildipine is a new dihydropyridine calcium entry blocker.

体外研究

体内研究

Gerbils are treated intraperitoneally with Lemildipine (0.1-3 mg/kg) just after release of the occlusion. Four days after the ischemia, they are fixed by perfusing 10% buffered-formalin, and the neuronal cell density (NCD, cell/mm) in the CA1 subfield is estimated under microscopy. The average NCD in the ischemic control group is 43±10.8 cells/mm, whereas Lemildipine (3 mg/kg) significantly ameliorates DND with an average NCD of 143±24.2 cells/mm (P<0.01). In addition, Lemildipine (3 mg/kg) significantly inhibits delayed neuronal death (DND) at 1, 2 and 4 weeks after transient ischemia: the average NCD of the Lemildipine and ischemic control groups are 80±9.4 (P<0.01) and 43±7.7 cells/mm, 92±13.7 (P<0.05) and 52±9.3 cells/mm, and 57±5.0 (P<0.01) and 43±12.4 cells/mm, respectively. In this experiment, Lemildipine (NB-818) exhibits a protective effect on DND in the hippocampal CA1 subfield after transient forebrain ischemia, and its effect persisted for up to 4 weeks. In normal Wistar rats (NWR), Lemildipine (NPK-1886) in doses of 3-30 mg/kg, p.o., produces a mild lowering of blood pressure. The depressor effect of Lemildipine is much the same as that of Nifedipine. In contrast, Lemildipine produces a significant decrease in the blood pressure of spontaneously hypertensive rats (SHR). Oral administration of Lemildipine in doses of 3, 10, 30 mg/kg produces a significant decrease in systolic blood pressure dose-dependently. The maximum decrease is observed 1-3 hr after administration. Comparing the hypotensive potency of Lemildipine and Nifedipine, their dose-response curves at the maximum response during the observation (for 24 hr) are analyzed by the least squares method, and the dose of 30% decrease in blood pressure from the control level (ED₃₀) are used as a measure of their potency. Lemildipine is 1.4 times stronger than Nifedipine; the ED₃₀ values of Lemildipine and Nifedipine are 10.2 mg/kg and 14.3 mg/kg, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (218.67 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1867 mL	10.9337 mL	21.8675 mL
5 mM	0.4373 mL	2.1867 mL	4.3735 mL
10 mM	0.2187 mL	1.0934 mL	2.1867 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.47 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.47 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。